A method of making a nucleic acid comprising: a) providing a linear vector, comprising: (i) providing a linear plasmid comprising a left arm comprising a left telomere, a right arm comprising a right telomere, and a first nucleic acid sequence comprising at least one endonuclease recognition site, (ii) providing a second nucleic acid sequence comprising a plurality of thymine nucleotides, wherein said plurality of thymine nucleotides comprises at least, greater than, equal to, or any number in between 130, 140, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or 550 covalently linked consecutive thymine nucleotides, and (iii) inserting the second nucleic acid into the linear plasmid, thereby joining said first nucleic acid sequence to said second nucleic acid sequence such that the second nucleic acid comprises an endonuclease cleavage site that is within the plurality of thymine nucleotides or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides from the 5' terminal thymine in the plurality of thymine nucleotides, and wherein said first nucleic acid is covalently linked to said second nucleic acid at one end of said second nucleic acid and, wherein said endonuclease recognition site is within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,47, 48, 49, 50, 51, 52, 53, 54 or 55 nucleotides of the endonuclease cleavage site, and (b) contacting said linear vector with an RNA polymerase in the presence of nucleotides, thereby generating the nucleic acid. a) providing a linear vector, comprising: (i) providing a linear plasmid comprising a left arm comprising a left telomere, a right arm comprising a right telomere, and a first nucleic acid sequence comprising at least one endonuclease recognition site, (ii) providing a second nucleic acid sequence comprising a plurality of thymine nucleotides, wherein said plurality of thymine nucleotides comprises at least, greater than, equal to, or any number in between 130, 140, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or 550 covalently linked consecutive thymine nucleotides, and (iii) inserting the second nucleic acid into the linear plasmid, thereby joining said first nucleic acid sequence to said second nucleic acid sequence such that the second nucleic acid comprises an endonuclease cleavage site that is within the plurality of thymine nucleotides or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides from the 5' terminal thymine in the plurality of thymine nucleotides, and wherein said first nucleic acid is covalently linked to said second nucleic acid at one end of said second nucleic acid and, wherein said endonuclease recognition site is within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,47, 48, 49, 50, 51, 52, 53, 54 or 55 nucleotides of the endonuclease cleavage site, and (i) providing a linear plasmid comprising a left arm comprising a left telomere, a right arm comprising a right telomere, and a first nucleic acid sequence comprising at least one endonuclease recognition site, (ii) providing a second nucleic acid sequence comprising a plurality of thymine nucleotides, wherein said plurality of thymine nucleotides comprises at least, greater than, equal to, or any number in between 130, 140, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or 550 covalently linked consecutive thymine nucleotides, and (iii) inserting the second nucleic acid into the linear plasmid, thereby joining said first nucleic acid sequence to said second nucleic acid sequence such that the second nucleic acid comprises an endonuclease cleavage site that is within the plurality of thymine nucleotides or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides from the 5' terminal thymine in the plurality of thymine nucleotides, and (b) contacting said linear vector with an RNA polymerase in the presence of nucleotides, thereby generating the nucleic acid.